Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 438 results for cardiovascular disease

  1. Automated blood pressure monitoring in people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial fibrillation?

    monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  2. Blood pressure targets for people with aortic aneurysm: What are the optimal blood pressure targets in adults with hypertension and aortic aneurysm, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  3. Blood pressure targets for people with prior ischaemic or haemorrhagic stroke: What are the optimal blood pressure targets in adults with prior ischaemic or haemorrhagic stroke, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  4. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

    HealthTech guidance
    Published
    24 March 2010
    View recommendations

    Sections for HTG213

  5. How we support healthtech developers

    With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.

  6. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    . Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  7. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

    Evidence summary
    Published
    23 September 2014

  8. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...

    Research recommendation
    Published
    9 June 2015

  9. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  10. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

    Technology appraisal guidance
    Published
    3 September 2025
    View recommendations

    Sections for TA1096

  11. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  12. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015

  13. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  14. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  15. Patient decision aids

    Intrabeam radiotherapy for treating early breast cancer Cardiovascular conditions (heart disease and stroke) How do I...